Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting
June 17 2019 - 6:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other
diseases of the eye today announced the appointment of Jeffrey
Calabrese, CPA, as Director of Accounting, reporting to Christopher
Staten, Aerie’s Vice President of Finance. Mr. Calabrese will lead
external financial reporting, technical accounting and equity
accounting. He most recently held related positions at Merck &
Co. and Helsinn Therapeutics (U.S.) Inc.
In connection with his acceptance of the position as Director of
Accounting, Mr. Calabrese will receive awards totaling 14,400 stock
options that will vest over 4 years, with 25% vesting on the first
anniversary of the hire date and the remainder vesting ratably on
each of the subsequent 36 monthly anniversaries of the hire date.
This award was made outside of Aerie’s stockholder-approved equity
incentive plan and was approved by the Company’s independent
directors as an inducement material to Mr. Calabrese entering into
employment with the Company in reliance on NASDAQ Listing Rule
5635(c)(4), which requires this public announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
retinal diseases and other diseases of the eye. Aerie's first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United
States in April 2018. In clinical trials of Rhopressa®,
the most common adverse reactions were conjunctival hyperemia,
corneal verticillata, instillation site pain, and conjunctival
hemorrhage. More information about Rhopressa®, including the
product label, is available at www.rhopressa.com. Aerie’s
second product for the reduction of elevated intraocular pressure
in patients with open-angle glaucoma or ocular hypertension,
Rocklatan® (netarsudil and latanoprost ophthalmic solution)
0.02%/0.005%, the first and only fixed-dose combination of
Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost,
has been approved by the FDA and is now available
in the United States. In clinical trials of
Rocklatan®, the most common adverse reactions were
conjunctival hyperemia, corneal verticillata, instillation site
pain, and conjunctival hemorrhage. More information about
Rocklatan®, including the product label, is available
at www.rocklatan.com. Aerie continues to focus on global
expansion and the development of additional product candidates and
technologies in ophthalmology, including for wet age-related
macular degeneration and diabetic macular edema. More information
is available at www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our expectations
regarding the commercialization and manufacturing of
Rhopressa® and Rocklatan® or any future product
candidates, including the timing, cost or other aspects of the
commercial launch of Rhopressa® and Rocklatan® or any
future product candidates; our commercialization, marketing,
manufacturing and supply management capabilities and strategies;
the success, timing and cost of our ongoing and anticipated
preclinical studies and clinical trials for Rhopressa® and
Rocklatan®, with respect to regulatory approval outside of the
United States or additional indications, and any future
product candidates, including statements regarding the timing of
initiation and completion of the studies and trials; our
expectations regarding the effectiveness of Rhopressa®,
Rocklatan® or any future product candidates; the timing of and
our ability to request, obtain and maintain FDA or other
regulatory authority approval of, or other action with respect to,
as applicable, Rhopressa®, Rocklatan® or any future product
candidates, including the expected timing of, and timing of
regulatory and/or other review of, filings for, as applicable,
Rhopressa®, Rocklatan® or any future product candidates; the
potential advantages of Rhopressa® and Rocklatan® or any
future product candidates; our plans to pursue development of
additional product candidates and technologies within and beyond
ophthalmology; our plans to explore possible uses of our existing
proprietary compounds beyond glaucoma, including development of our
retina program; our ability to protect our proprietary technology
and enforce our intellectual property rights; and our expectations
regarding strategic operations, including our ability to in-license
or acquire additional ophthalmic products, product candidates or
technologies. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events, competitive
dynamics, industry change and other factors beyond our control, and
depend on regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with
the Securities and Exchange Commission (SEC). In
particular, FDA approval of Rhopressa® and
Rocklatan® do not constitute FDA approval of
AR-1105, AR-13503 or any future product candidates, and there can
be no assurance that we will receive FDA approval for
AR-1105, AR-13503 or any future product
candidates. FDA approval of Rhopressa® and
Rocklatan® also do not constitute regulatory approval of
Rhopressa® and Rocklatan® in jurisdictions
outside the United States and there can be no assurance
that we will receive regulatory approval for Rhopressa® and
Rocklatan® in jurisdictions outside the United States. In
addition, the acceptance of the INDs by the FDA for
AR-1105 and AR-13503 does not constitute FDA approval of
AR-1105 or AR-13503 and the outcome of later clinical trials for
AR-1105 or AR-13503 may not be sufficient to submit an NDA with
the FDA or to receive FDA approval.
Forward-looking statements are not guarantees of future performance
and our actual results of operations, financial condition and
liquidity, and the development of the industry in which we operate
may differ materially from the forward-looking statements contained
in this press release. Any forward-looking statements that we make
in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190617005001/en/
Media: Tad Heitmann 949-526-8747;
theitmann@aeriepharma.comInvestors: Ami Bavishi 908-947-3949;
abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024